Clinic News

Latest in Cardiology

DANCAVAS 2 and ABC-AF Trials Explore Personalized Treatments For CV Prevention
New research exploring the potential of personalized treatments to detect and prevent cardiovascular disease was part of a prevention-focused hot line Session at ESC Congress 2025.
HI-PRO: Apixaban Lowers Risk of VTE in Patients With Transient Provoking Factors
At one year, low-intensity apixaban therapy results in lower risk of symptomatic recurrent venous thromboembolism (VTE) compared to placebo in patients with provoked VTE and enduring risk factors. Furthermore, it carries a low risk of major bleeding, according to efficacy and safety results of the HI-PRO trial, presented during ESC Congress 2025 and simultaneously published […]
PREVENT-MINS: Ivabradine to Reduce Risk of Myocardial Injury After Noncardiac Surgery
Ivabradine did not reduce the risk of myocardial injury after noncardiac surgery (MINS) compared with placebo in patients over the age of 45 years with, or at risk of, atherosclerotic disease, according to findings from the PREVENT-MINS trial presented at ESC Congress 2025.
VICTORION-Difference: Inclisiran-Based Treatment Strategy For Patients With Hypercholesterolemia
Inclisiran on top of individually optimized lipid-lowering therapy helped more patients with hypercholesterolemia at high/very high risk of cardiovascular events achieve LDL cholesterol (LDL-C) goals compared with placebo, based on findings from the VICTORION-Difference trial presented at ESC Congress 2025.
BaxHTN and KARDIA-3 Trials Explore Efficacy of HTN Treatments
Two hot line trials â€“ BaxHTN and KARDIA-3 â€“ presented at ESC Congress 2025 explore treatment options for patients with uncontrolled hypertension.
Essence-TIMI 73b: Olezarsen Significantly Lowers Triglycerides in Moderate Hypertriglyceridemia With Elevated CV Risk
Treatment with olezarsen significantly reduced triglyceride levels at six months compared to placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to results of the Essence-TIMI 73b study presented during ESC Congress 2025 and simultaneously published Aug. 30 in NEJM.
REFINE-ICD: Efficacy of ICD Therapy in Higher Risk Post-MI Patients With Better-Preserved LV Function
Prophylactic ICD therapy did not reduce mortality in patients with a prior myocardial infarction (MI), persistent moderate left ventricular (LV) systolic dysfunction and abnormal ECG markers, according to results from the REFINE-ICD trial presented at ESC Congress 2025.
Beta-Blocker Therapy Following MI the Focus of Late-Breaking Research at ESC Congress 2025
Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025.
VICTOR AND VICTORIA: Late-Breaking Science Explore Benefits of Vericiguat in Treating Patients With HFrEF
Vericiguat did not reduce the risk of a composite endpoint of time to cardiovascular death or heart failure (HF) hospitalization among patients with HF and reduced ejection fraction (HFrEF) without recent HF worsening, based on findings from the VICTOR trial...
MAPLE-HCM: Aficamten Monotherapy vs. Metoprolol Monotherapy in Patients With Symptomatic Obstructive HCM
Aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics and decreasing symptoms among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to results from the MAPLE-HCM trial...